Sentence examples for mortality propensity from inspiring English sources

The MOR is the median odds ratio between the patient in the hospital with higher mortality propensity and the patient in the hospital with lower mortality propensity.

Variation in the mortality propensity between hospitals is accommodated by assuming a normal distribution for ui with mean zero and variance τ.

Finally, 90-day mortality (propensity-weighted) by refractory septic shock in patients randomized to DrotAA or placebo who received steroids was similar to those without steroid therapy (25.6, 28.8, 25.2 and 28.4%, respectively).> -wrap-foot> DrotAA, drotrecogin-alfa activated.

Cox regression analysis was used to assess differences in 28-day in-hospital mortality between propensity score-matched patients with and without antithrombin treatment [24].

Table 3 summarises the relationship between vasoactive therapy and inhospital mortality after propensity score adjustment.

In the 732 patients with CHF, vasoactive therapy remained significantly correlated with inhospital mortality after propensity score adjustment (OR=2.00, p=0.004).

Likewise, in the 354 sepsis patients, vasoactive therapy was a significant predictor of in-hospital mortality with propensity score adjustment (OR=2.84, p<0.001).

The Kaplan-Meier estimator for 28-day mortality using propensity score matching was significantly lower in the etomidate cohort than in the non-etomidate cohort and showed a hazard ratio for death in the ICU in the etomidate cohort, as compared with the non-etomidate cohort, of 0.33 (0.112 to 0.988).

To remove any bias of confounding variables for the association between the areas of ICU admission and mortality, a propensity score was estimated for each of the ICU areas, with the following variables considered as factors: type of admission, source of admission, comorbidities, age, sex, mechanical ventilation, haemofiltration or haemodialysis, infection, SAPS II score and type of microorganism.

Separate analyses on propensity-score-matched populations confirmed these data: 1-year mortality in propensity-score-matched cohorts of early survivors was significantly higher in those with CS at the acute stage (HR: 2.49, 95% CI: 1.43, 4.33, P = 0.001).

By contrast, mortality of propensity-matched patients treated conventionally was comparable to that of ECMO patients in French ICUs of the REVA network.